Insider trades
Helen Louise Collins, Chief Officer of Enliven Therapeutics ELVN, has filed 0 purchases and 16 sales on the open market. Over the past 12 months that comes to a net sale of $4.6M. The latest trade was on 06/17.
Helen Louise Collins
Chief Medical Officer
- Company
- Enliven Therapeutics ELVN
- First filing
- 23/02/27
- Trades
- 49 trades
- Buys / sales
- 0 / 16
- 12-month net buying
- −$4.6M
- Last trade
- 06/17
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
ELVN | Open-market sale10b5-1 plan | 06/17 | 06/22 | 5,000 sh3 trades | $43.80avg. | $219,016.99 | −16.7% |
ELVN | Open-market sale10b5-1 plan | 05/18 | 05/20 | 5,000 sh3 trades | $39.79avg. | $198,962.08 | −16.7% |
ELVN | Open-market sale10b5-1 plan | 04/17 | 04/21 | 5,000 sh3 trades | $47.67avg. | $238,364.27 | −16.7% |
| Open-market sale10b5-1 plan | 03/25 | 03/27 | 40,000 sh | $35.10 | $1,404,000 | −61.5% | |
| Open-market sale10b5-1 plan | 03/17 | 03/19 | 5,000 sh | $27.76 | $138,800 | −16.7% | |
ELVN | Open-market sale10b5-1 plan | 03/09–03/10 | 03/11 | 40,000 sh2 trades | $30.06avg. | $1,202,521.93 | −61.5% |
| Open-market sale10b5-1 plan | 02/17 | 02/19 | 45,000 sh | $26.17 | $1,177,650 | −64.3% | |
| Open-market sale10b5-1 plan | 24/10/18 | 24/10/22 | 816 sh | $30.00 | $24,480 | −100.0% | |
| Open-market sale10b5-1 plan | 24/04/11 | 24/04/15 | 20,000 sh | $25.07 | $501,400 | −100.0% |